Loading clinical trials...
Loading clinical trials...
A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab, Administered With Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants With Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer
Conditions
Interventions
Pembrolizumab SC
Pembrolizumab IV
+5 more
Locations
126
United States
St. Bernards Medical Center ( Site 0103)
Jonesboro, Arkansas, United States
St Joseph Heritage Healthcare-Oncology ( Site 0102)
Fullerton, California, United States
Cancer Blood and Specialty Clinic ( Site 0105)
Los Alamitos, California, United States
PIH Health Hematology Medical Oncology ( Site 0106)
Whittier, California, United States
Holy Cross Hospital ( Site 0017)
Fort Lauderdale, Florida, United States
Memorial Regional Hospital-Memorial Cancer Institute ( Site 0104)
Hollywood, Florida, United States
Start Date
August 5, 2021
Primary Completion Date
April 4, 2023
Completion Date
October 14, 2026
Last Updated
December 3, 2024
NCT06043817
NCT06758401
NCT07431827
NCT06427941
NCT06476808
NCT05142189
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions